Investors Sought In Hong Kong
Medical equipment developer Jupiter Diagnostics has received renewed support from one of its largest shareholders as it seeks to bolster its patents and take its advanced blood testing technology to market.
“Jupiter Diagnostics Holding Company Limited and L3 Technology Limited, the two companies which hold Jupiter’s patents remain in existence, while we make one further attempt to continue development,” Chris Ball, CEO of Jupiter Diagnostics, said
The tech startup has previously raised several rounds of funding but currently faces steep costs to continue development following insolvency of its operating company Jupiter Diagnostics Limited
Jupiter Diagnostics Holding Company Ltd and L3 Technology the two companies in the group which hold the patents remain solvent however and the management are currently seeking additional investment in Hong Kong.
“George Cautherley, Jupiter’s largest shareholder, is looking to raise funds to continue Jupiter’s operations or sell on the technology in Hong Kong. He hopes to have more information to share with the board in the autumn, and has agreed to continue to fund Jupiter’s key patents in the meantime,” Ball added.
Jupiter Diagnostics last secured a lift round in January 2017 after raising in the region of £1,427,377.